GRÜNENTHAL PARTNERS WITH DKSH TO BRING FOUR IMPORTANT PAIN MEDICINES TO EIGHT NEW MARKETS IN ASIA-PACIFIC

Contributed by: News Aktuell

Issued by news aktuell/OTS on behalf of Grünenthal Group

Logo

Tags

Medical profession

Joint venture

More Like This

GRÜNENTHAL LICENSES EXCLUSIVE SOUTH KOREAN RIGHTS TO QUTENZA® TO BCWORLD PHARM

GRÜNENTHAL LICENSES EXCLUSIVE AUSTRALIAN RIGHTS TO QUTENZA® TO CLINECT

APOTEX LICENSES EXCLUSIVE CANADIAN RIGHTS TO QUTENZA® FROM GRÜNENTHAL

GRÜNENTHAL TAKES FULL OWNERSHIP OF GRÜNENTHAL MEDS, THE JOINT VENTURE ESTABLISHED WITH KYOWA KIRIN FOR ITS ESTABLISHED MEDICINES BRANDS

Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in South Korea for the preventive treatment of migraine

Lundbeck receives marketing authorization for Vyepti® (eptinezumab) in Japan for the prevention of migraine attacks

PR Newswire associated0

Zentiva Joins the Call to Action to Finalize Pharmaceutical Reform and Secure Sustainable Healthcare for People in Europe